Methamphetamine associated psychosis. Mental and behavioural disorders due to use of hallucinogens
Conditions
Interventions
Intervention 1: Hypiran medication will be prescribed in the intervention group. The dosage of hypiran use is 60 drops three times a day for one month. (60 drops of hypiran has 0.3 mg of the acti
Treatment - Drugs
Hypiran medication will be prescribed in the intervention group. The dosage of hypiran use is 60 drops three times a day for one month. (60 drops of hypiran has 0.3 mg of the active ingredient ca
Placebo will be prescribed in the control group. The dosage of placebo use is 60 drops three times a day for one month.
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: the patients who are current methamphetamine users have been admitted to the hospital; age between 18 and 70 years old; they have met the criteria for methamphetamine induced psychotic disorder according to DSM-5. Exclusion criteria: having a diagnosis of bipolar I and II disorder; substance induced mood disorder (with manic symptoms); liver and kidney diseases.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glutathione Peroxidase. Timepoint: before intervention, 14 and 28 days after intervention. Method of measurement: colorimetry.;Glutathione Reductase. Timepoint: before intervention, 14 and 28 days after intervention. Method of measurement: colorimetry.;Total Antioxidant Capacity. Timepoint: before intervention, 14 and 28 days after intervention. Method of measurement: colorimetry.;Nitric Oxide. Timepoint: before intervention, 14 and 28 days after intervention. Method of measurement: Elisa.;Malondialdehyde. Timepoint: before intervention, 14 and 28 days after intervention. Method of measurement: Elisa.;Selenoprotein1. Timepoint: before intervention, 14 and 28 days after intervention. Method of measurement: Elisa.;Methamphetamine. Timepoint: 14 after intervention. Method of measurement: HPLC. | — |
Secondary
| Measure | Time frame |
|---|---|
| BDNF. Timepoint: before intervetion and 28 days after intervention. Method of measurement: ELISA.;VEGF. Timepoint: before intervetion and 28 days after intervention. Method of measurement: ELISA.;DTNBP1. Timepoint: before intervetion and 28 days after intervention. Method of measurement: ELISA.;IL-6. Timepoint: before intervetion and 28 days after intervention. Method of measurement: ELISA. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mehrdad Eftekhar
Iran University of Medical Sciences
Outcome results
None listed